Morren John A, Li Yuebing
Staff, Neuromuscular Center, and Program Director, Neuromuscular Medicine Fellowship, Neurological Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Cleve Clin J Med. 2023 Feb 1;90(2):103-113. doi: 10.3949/ccjm.90a.22017.
Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.
重症肌无力是一种神经肌肉接头传递障碍性疾病，是由针对神经肌肉接头突触后成分的抗体所致。其临床特征是骨骼肌出现易疲劳性无力，在患者中其部位和严重程度往往有所不同。治疗方法包括使用吡啶斯的明、免疫疗法和胸腺切除术。治疗通常根据疾病严重程度、抗体状态、合并症及其他因素进行个体化调整。本综述采用问答形式，提供有关重症肌无力的最新、高价值且与临床相关的信息。
